Imatinib mesylate has anti-inflammatory properties, because it is a specific and potent inhibitor of several protein tyrosine kinases. Paniagua et al. have investigated imatinib's mechanism of ...

Imatinib mesylate is a tyrosine kinase inhibitor used in the treatment of cancers including chronic myeloid leukemia. In their study, however, Kerkelä et al. report that this drug can be ...

Background and Objective: Imatinib mesylate is the first effective therapy for advanced unresectable gastrointestinal stromal tumours (GIST). Adoption of this therapy in clinical practice is ...

The Food and Drug Administration (FDA) has approved Shorla Oncology‘s IMKELDI for the treatment of specific leukaemia cancer ...

Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on Inhibikase Therapeutics (IKT – Research Report). The associated ...

Detailed price information for Inhibikase Therapeutics Inc (IKT-Q) from The Globe and Mail including charting and trades.

Stivarga (BAY 73-4506) is the brand name for the generic chemotherapy agent regorafenib, an oral anticancer medication approved by the FDA for individuals with locally advanced, unresectable, or ...